Background/Aims Bariatric intervention has been reported to be an effective way to improve metabolic dysfunction-associated steatotic liver disease (MASLD) in obese individuals. The current systemic review aimed to assess the changes in MRI-determined hepatic proton density fat fraction (MRI-PDFF) and nonalcoholic fatty liver disease activity score (NAS) after bariatric surgery or intragastric balloon/gastric banding in MASLD patients with obesity.
Methods We searched various databases including PubMed, OVID Medline, EMBASE, and Cochrane Library. Primary outcomes were the changes in intrahepatic fat on MRI-PDFF and histologic features of metabolic dysfunction-associated steatohepatitis (MASH).
Results Thirty studies with a total of 3,134 patients were selected for meta-analysis. Bariatric intervention significantly reduced BMI (ratio of means, 0.79) and showed 72% reduction of intrahepatic fat on MRI-PDFF at 6 months after bariatric intervention (ratio of means, 0.28). Eight studies revealed that NAS was reduced by 60% at 3–6 months compared to baseline, 40% at 12–24 months, and 50% at 36–60 months. Nineteen studies revealed that the proportion of patients with steatosis decreased by 44% at 3–6 months, 37% at 12–24 months, and 29% at 36–60 months; lobular inflammation by 36% at 12–24 months and 51% at 36–60 months; ballooning degeneration by 38% at 12–24 months; significant fibrosis (≥F2) by 18% at 12–24 months and by 17% at 36–60 months after intervention.
Conclusions Bariatric intervention significantly improved MRI-PDFF and histologic features of MASH in patients with obesity. Bariatric intervention might be the effective alternative treatment option for patients with MASLD who do not respond to lifestyle modification or medical treatment.
Citations
Citations to this article as recorded by
Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans Anna Giannakogeorgou, Michael Roden, Kalliopi Pafili Hormones.2026; 25(1): 61. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults Herbert Tilg, Salvatore Petta, Norbert Stefan, Giovanni Targher JAMA.2026; 335(2): 163. CrossRef
National trend and impact of compensated cirrhosis in patients who underwent metabolic and bariatric surgery: a Nationwide Readmissions Database study Ali Esparham, Stephen Phillippe, Zhamak Khorgami Surgical Endoscopy.2026; 40(3): 2559. CrossRef
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2026; 32(1): 368. CrossRef
Rhinorrhea and Hiccups After Bariatric Surgery: Exploring Associations with Psychological and Behavioral Factors Marcello Agosta, Maria Sofia, Simona Santonocito, Sara D’Amato, Chiara Mazzone, Cristina Agata Ranno, Salvatore Camiolo, Gaetano La Greca, Saverio Latteri Obesities.2026; 6(1): 13. CrossRef
Ultrasound-derived Fat Fraction for Pre-operative Prediction and Monitoring of Hepatic Steatosis Normalization After Metabolic Surgery in Patients With Obesity Die Hu, HuaWu Yang, GeMei Yu, Li Wei, Ying Liu, Hong Zhou, WeiWen Cai, Hong Wen, Guo Li, Shuang Wu, Yang Zhou Ultrasound in Medicine & Biology.2026; 52(6): 1062. CrossRef
Impact of pathologically diagnosed metabolic dysfunction-associated steatohepatitis on weight loss outcomes following sleeve gastrectomy Yunmiao Pan, Yunfei Qu, Hanchen Ma, Maoge Wang, Mingwei Zhong, Sanyuan Hu Frontiers in Medicine.2026;[Epub] CrossRef
Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial Sebastian M. Meyhöfer, Bertrand Cariou, Cintia Cercato, Helen M. Colhoun, John Deanfield, Michelle T. Long, Ole Kleist Jeppesen, A. Michael Lincoff, Ildiko Lingvay, Jorge Plutzky, Philip N. Newsome, Stephen J. Nicholls, Maria Quiroga, Ferruccio Santini, A Nature Medicine.2026; 32(5): 1686. CrossRef
Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials Doha Jaber, Inas Jaber, Ayah Abu Lehia, Thekrayat Asad, Hazem Ayesh Endocrinology, Diabetes & Metabolism.2026;[Epub] CrossRef
The impact of bariatric and metabolic surgery on the levels of circulating growth differentiation factor 15 in humans Victor Yassuda, Beatriz Sequeira, Ana Luísa De Sousa-Coelho Journal of Physiology and Biochemistry.2026;[Epub] CrossRef
Kv1.3 regulates macrophage immune function through PI3K/AKT signaling pathway to alleviate metabolic dysfunction-associated steatohepatitis Ting Ke, Wen-Jun Zhen, Xi-xi Chen, Hao Wang, Shi Chen, Yuan-yuan Tian, Ye-tao Wang, Lei Zhang, Bao-ming Wu Journal of Molecular Medicine.2026;[Epub] CrossRef
Pilot Study on the Use of Rheology and Low Field Nmr to Characterize the Liver of Obese Patients Undergoing Metabolic and Bariatric Surgery Alice Biasin, Silvia Palmisano, Michela Abrami, Deborah Bonazza, Fabrizio Zanconati, Domenico Tierno, Federica Tonon, Nhung Hai Truong, Thanh Dang Minh, Ralf Weiskirchen, Fulvia Felluga, Bruna Scaggiante, Mario Grassi, Gabriele Grassi International Journal of Molecular Sciences.2026; 27(9): 4040. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Diagnostic Pathways, Noninvasive Fibrosis Assessment, and Therapeutic Strategies Andrzej Bazan, Oliwer Plichta, Natalia Radzinska Cureus.2026;[Epub] CrossRef
Steatotic liver disease and cardiovascular-kidney-metabolic syndrome Heidi Kolodziejczyk, Elena Ignatiev Nursing.2026; 56(6): 25. CrossRef
Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast Megha Poddar, Joe Nadglowski Advances in Therapy.2026; 43(9): 3675. CrossRef
Pharmacologic management of metabolic and alcohol-associated liver disease Mangesh Pagadala, Sajid Jalil, Nicholas Dunn, Ashwani K. Singal Metabolism and Target Organ Damage.2026;[Epub] CrossRef
Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications Kenneth Tachi, Adwoa Agyei-Nkansah, Yacoba Atiase, Bright Forkuo, Victoria Akosua Agyen-Frimpong BMJ Open Gastroenterology.2026; 13(1): e002294. CrossRef
Imaging-based fibrosis assessment and risk stratification in MASLD Shunqin Jin, Tao Zhou, Dachuan Jin, Jiahao Xie, Guoping Sheng, Hongzhi Li, Guangming Li, Chuan Qin, Peng Gao Frontiers in Medicine.2026;[Epub] CrossRef
Impact of nonalcoholic fatty liver disease on the response to pegylated interferon-α therapy in patients with chronic hepatitis B Huiqing Liang, Yizhi Xie, Yan Dai, Xiaorong Yang, Xiaoting Zheng, Jiaen Yang, Yaoyu Liu, Chuncheng Wu, Siyan Chen, Manying Zhang, Hongli Zhuang, Li Lin, Shaodong Chen, Peter Pelka Microbiology Spectrum.2026;[Epub] CrossRef
DCES Guide to Liver Disease Sara (Mandy) Reece, Hyojung Choi, Jennifer N. Clements ADCES in Practice.2026;[Epub] CrossRef
Body composition changes after bariatric surgery in adults with obesity and hepatic steatosis Lilian Kethelyn Teixeira Schmitt, Luis F Ferreira, Claudio Cora Mottin, Bruna Goularth Lacerda, Paula Rosales Zubiaurre, Joise Munari Teixeira, Claudio A Marroni, Sabrina Alves Fernandes World Journal of Gastrointestinal Surgery.2026;[Epub] CrossRef
MRI in MASLD: technical foundations and guideline-based applications Jun Pu, Liang Zhu, Yanlei Wu, Fan Ping, Jia Xu, Kang Zhou, Xuan Wang, Jie Pan BMJ Open Gastroenterology.2026; 13(1): e002471. CrossRef
Bariatric surgery as a therapeutic strategy for metabolic dysfunction-associated steatotic liver disease in patients with obesity: a narrative review Yuri Cho Journal of the Korean Medical Association.2026; 69(8): 612. CrossRef
Hepatic immune microenvironment dynamics in severe obesity and post-bariatric surgery: insights from immunohistochemical analysis Alina-Iuliana Onoiu, Sergio González-Serrano, Vicente Cambra-Cortés, Andrea Jiménez-Franco, Carmen Guilarte, Karla Beatriz Peña, Francesc Riu, Jordi Camps, Jorge Joven, David Parada Frontiers in Immunology.2026;[Epub] CrossRef
Associations of General and Central Obesity with Cardiovascular Risk by Menopausal and MASLD Status Dong Yun Kim, Kyu-Na Lee, Kyung-Do Han, Beom Kyung Kim Biomedicines.2026; 14(9): 1985. CrossRef
Molecular smugglers in obesity-driven MASLD: snitching on adipose-derived extracellular vesicles Qiuyang Chen, Taisiia Shevchenko, Dewen Zhan, Ningning Ma, Sander Lefere, Joost Boeckmans, Joery De Kock, Freddy Van Goethem, Yong He, Tamara Vanhaecke, Robim M. Rodrigues Acta Pharmaceutica Sinica B.2026;[Epub] CrossRef
Metabolic and Bariatric Surgery as a Therapeutic Option for MASLD: Outcome, Mechanism, and Long-Term Implications Christopher Tuffs, Anca Laura Amati, Daniar Amin, Sonali Raj, Thilo Sprenger, Andreas Hecker, Martin Schneider, Martin Reichert, Moritz J. Strowitzki Zeitschrift für Gastroenterologie.2026; 64(09): 1291. CrossRef
Bariatric surgery may alleviate MASLD by restoring mitochondria-lipid droplet structural and functional integrity through suppression of the Mitochondrial Fission Factor-Perilipin 5 axis Yuze Sun, Yuxuan Liu, Xiyu Chen, Shizhou Deng, Ning Zhang, Feifei Wu, Dong Fan, Yayun Wang, Yanling Yang Molecular Biomedicine.2026;[Epub] CrossRef
Serial changes in metabolic dysfunction-associated steatotic liver disease after sleeve gastrectomy and their associations with abdominal adiposity: a prospective cohort study Chung-Yi Yang, Jian-Han Chen, Chung-Yen Chen, Cheng-Yi Kao, Shiu-Feng Huang, Wen-Yu Chang, Hung-Pin Tu, Jee-Fu Huang, Ming-Lung Yu, Chi-Ming Tai Surgery for Obesity and Related Diseases.2025; 21(5): 537. CrossRef
Bariatric nutrition and evaluation of the metabolic surgical patient: Update to the 2022 Obesity Medicine Association (OMA) bariatric surgery, gastrointestinal hormones, and the microbiome clinical practice statement (CPS) Sue Benson-Davies, Kirsten Frederiksen, Rutuja Patel Obesity Pillars.2025; 13: 100154. CrossRef
Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Xiao-Song Li, Xi-Ping Shen, Hang Li Clinical and Molecular Hepatology.2025; 31(1): e15. CrossRef
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Yuri Cho, Dae Won Jun Clinical and Molecular Hepatology.2025; 31(1): e103. CrossRef
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot Eda Kaya, Wing-Kin Syn, Paul Manka Current Opinion in Gastroenterology.2025; 41(3): 104. CrossRef
Perioperative Screening for Metabolic Dysfunction Associated Steatotic Liver Disease in People Undergoing Bariatric Surgery: A Pilot Study David M. Williams, Thinzar Min, Andrew Beamish, Jeffrey W. Stephens Obesity Surgery.2025; 35(5): 1963. CrossRef
Impact of Severity of Metabolism-Related Fatty Liver Disease Based on Pathologic Grading on Outcomes after Sleeve Gastrectomy 云飞 曲 Journal of Clinical Personalized Medicine.2025; 04(02): 826. CrossRef
Cambios biométricos y metabólicos a un año de seguimiento en pacientes con obesidad e hígado graso sometidos a gastroplastia endoscópica en manga-EndoSleeve (método Apollo) Diego Schwarzstein, Lissette Batista, Patricia Gonçalves, Luis Yip, Leoniana Bustillos, Mar Bacardit, Josep Merlo Revista de la Sociedad Española de Cirugía de Obesidad y Metabólica y de la Sociedad Española para el Estudio de la Obesidad.2025;[Epub] CrossRef
Liver and obesity: a narrative review Amedeo Lonardo, Ralf Weiskirchen Exploration of Medicine.2025;[Epub] CrossRef
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders Marwin A. Farrugia, Enzo Pini, Albert Tran, Nicolas Chevalier, Rodolphe Anty, Philippe Gual Current Obesity Reports.2025;[Epub] CrossRef
Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study Jheng-Yan Wu, Yu-Min Lin, Wan-Hsuan Hsu, Ting-Hui Liu, Ya-Wen Tsai, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Chih-Cheng Lai Hepatology International.2025; 19(5): 1087. CrossRef
Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD) Neha Gupta, Kavita Singh Journal of Molecular Histology.2025;[Epub] CrossRef
Duodenal mucosal ablation: An emerging therapeutic concept for metabolic dysfunction-associated fatty liver disease Cornelius J Fernandez, Sweekruti Jena, Vijaya Lakshmi, Joseph M Pappachan World Journal of Gastroenterology.2025;[Epub] CrossRef
Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet–induced Mouse Model Huimin Xia, Yuqin Min, Yuhua Wang, Siyu Gao, Hailing Wang, Fuhua Yan, Ruixin Liu, Jiqiu Wang, Xuejiang Gu, Tingting Bo Radiology.2025;[Epub] CrossRef
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era Dragoș Lupu, Camelia Cornelia Scârneciu, Diana Țînț, Cristina Tudoran Journal of Clinical Medicine.2025; 14(17): 5993. CrossRef
ISImatsuda as a potential predictor of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus Jing Liu, Yueqiu Wang, Xinghang Zhou, Zaixin Wen, Yu Chen, Yiqiong Sun, Shuaiying Su, Weiwei Lin, Ruiting Shen, Xiaoyu Sun, Hongru Li, Xia Yu, Mingchen Zhang Frontiers in Medicine.2025;[Epub] CrossRef
Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome Richard H. Goodheart, Oyekoya T. Ayonrinde Heart, Lung and Circulation.2025; 34(10): 1050. CrossRef
Prospective evaluation of a structured group education programme for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Thomas Crame, Rachel Howarth, Elizabeth Johnstone, Hollie Smith, Stuart McPherson, Kate Hallsworth Frontline Gastroenterology.2025; : flgastro-2025-103280. CrossRef
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas Biomedicines.2025; 13(10): 2437. CrossRef
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef
Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study José Ignacio Martínez-Montoro, Isabel Arranz-Salas, Carolina Gutiérrez-Repiso, Ana Sánchez-García, Luis Ocaña-Wilhelmi, José M. Pinazo-Bandera, Diego Fernández-García, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés, Eduardo García-Fuente Nutrients.2024; 16(22): 3857. CrossRef
First
Prev
